Blueprint Genetics

Executive Summary

Blueprint Genetics is a Finnish clinical genetic diagnostics company founded in 2012 that specializes in next-generation sequencing (NGS) testing for medical professionals worldwide. The company offers a comprehensive portfolio of over 200 tests across 14 medical specialties, including panel tests, whole exome sequencing, and single-gene tests, all designed to deliver actionable insights for clinical decision-making. By focusing on high analytical sensitivity and specificity, Blueprint Genetics has established itself as a trusted partner in rare disease diagnostics, cardiology, and oncology, among other fields. Its mission is to accelerate the adoption of precision medicine by providing accurate, timely, and cost-effective genetic testing services. Despite being privately held and not disclosing financials, Blueprint Genetics is well-positioned in the growing genetic testing market, valued at over $20 billion globally. The company has built a strong reputation for quality, with ISO 15189 accreditation and a track record of high diagnostic yields. However, it faces competition from larger players like Invitae and Illumina. Key catalysts include expansion of its test menu, strategic partnerships with pharmaceutical companies for companion diagnostics, and potential expansion into new geographic markets. The company's ability to innovate and maintain clinical utility will be critical for its growth trajectory.

Upcoming Catalysts (preview)

• Q3 2026Launch of new comprehensive pan-cancer panel70% success
• Q4 2026Strategic partnership with a major pharma for companion diagnostics50% success
• TBDExpansion into US market via CLIA certification30% success